The latest genitourinary oncology news
Penile squamous cell carcinoma: improving outcomes
Penile squamous cell carcinoma is a rare malignancy with limited treatment options and poor prognosis,…
Browsing: GU Cancers
Study suggests improvements needed for patient-reported outcome data in genitourinary cancer clinical studies
Patient-reported outcomes are important indicators of how cancer drugs impact patients’ lives. By assessing the…
ASCO GU 2024: Study shows positive results for patients with muscle-invasive urothelial carcinoma
Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have…
ASCO GU 2024: Subcutaneous nivolumab as effective as IV for renal cell carcinoma with much faster treatment time
Subcutaneous injection of the immunotherapy nivolumab is non-inferior to intravenous delivery and dramatically reduces treatment…
ASCO GU 2024: Combination of cabozantinib and atezolizumab offers hope for patients with type of advanced prostate cancer with poor prognosis
Patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic nodal or visceral metastasis who were…
Prostate cancer: Newly-developed inhibitor shows massive potential
More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand…
Association of molecular subtypes in bladder cancer with response to neoadjuvant chemotherapy, progression, and survival
Considering the molecular subtype of muscle-invasive bladder cancer (MIBC) based on differences in tumour RNA…
ESMO 2023: Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy…
ANZUP Cancer Trials Group Wraps Up Successful 2023 ASM
The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group recently held another…
The ball’s in your court | Below the belt cancer free community Q&A
Hear from some of the world’s leading below the belt researchers and patients through ANZUP’s…